470
JENKINS ET AL (20) were obtained from the AIDS Research and Reference Reagent Program and maintained in continuous culture in RPMI medium supplemented with 10% FCS, 100 units penicillin per mL, and 100 pg streptomycin per mL (hereafter referred to as complete medium). Cells were subcultured twice a week.
Sera. As a positive standard and interassays control, an HIVpositive reference serum pool was created from serum samples of 120 individuals with HIV antibodies by both ELISA and immunofluorescence. Ten sera lacking HIV antibodies by ELISA were obtained from the same source for the determination of cutoff values for significant ADCC. Negative control sera for use in assays were obtained from healthy adult volunteers at low risk of HIV infection and confirmed negative for HIV antibody by ELISA. All sera were depleted of complement in a 56°C water bath for 30 min before aliquots were taken and stored at -70°C.
Zmmunoj7uorescence. Live cell indirect surface antigen immunofluorescence was performed with a modification of the method of Blumberg et al. (21) . A total of lo6 H9 or HXB cells were washed in PBS and incubated with 1 mL 1: 10 dilution of HIV-negative serum or positive reference serum for 30 min at 4°C. Cells were washed twice in PBS and incubated with FITClabeled goat anti-human serum (Chemicon, Temecula, CA) diluted 1:40 in PBS for 30 min at 4°C. Cells were washed twice and examined immediately without fixation for fluorescence. and PBMC isolated by density gradient centrifugation with Ficoll-Hypaque (Pharmacia, Piscataway, NJ). Cells were washed four times in HBSS before use in cytotoxicity assays. When umbilical cord samples were compared with adult PBMC, the adult volunteer was phlebotomized within 3 h of the time of delivery and collection of the umbilical cord samples. Leukocyte fractions were prepared as follows. PMN were purified by sedimentation of blood after addition of '/lo volume 3% dextran (Sigma Chemical Co., St. Louis, MO) followed by Ficoll-Hypaque density centrifugation. Adherent and nonadherent fractions of PBMC (monocyte-macrophages and lymphocytes) were prepared as described earlier (22) . Briefly, PBMC from Ficoll interfaces were washed once in HBSS and enumerated by counting in a hemocytometer. Cells were suspended in RPMI medium supplemented with 10% autologous plasma at a concentration of 5 x lo6 cells per mL, and 5 to 10 mL of cell suspension were added to 10-cm plastic Petri dishes (Falcon, Oxnard, CA). Cells were allowed to adhere for 2 h at 37°C in humidified air enriched with 5% COz. Nonadherent cells were decanted from the dishes, and the adherent cells were washed three times with HBSS, then removed with a cell lifter (Costar, Cambridge, MA).
The resulting nonadherent (predominantly lymphocyte) and adherent (predominantly monocyte-macrophage) cell populations were further characterized by latex bead ingestion as described (22) . Ten pL of 10% latex particles (Dow Diagnostics, Indianapolis, IN) or medium control were added to 1.5 x lo6 cells in 1 mL of complete medium. After 2 h of incubation, the cells were washed and added to cytotoxicity assays or examined microscopically for the ingestion of beads. Of the adherent cells, 88% ingested latex beads, whereas fewer than 5 % of nonadherent cells ingested latex.
Cytotoxicity assay. ADCC and NKC of HIV-infected cells were measured using a modification of the assay of Blumberg et al. (1 1) . Approximately lo6 H9/HXB-2 target cells were labeled with 100 pCi of 51Cr (sp act 250 mCi/mg chromium) (Amersham, Arlington Heights, IL) in a volume of 100 pL at 37°C for 1 h and then washed four times in complete medium. Because H9/ HXB-2 cells internalized 1-2 cpm of 51Cr per cell, we were able to use only 2000 target cells per well in cytotoxicity assays. Target cells were consistently greater than 95% viable by trypan blue vital staining before addition to assays. A total of 2 x lo3 target cells suspended in 50 pL of complete medium were added to each well of round-bottom microtiter trays (Corning, Corning, N Y ) .
effector cells (PBMC or subsets) were then added at various effector-to-target ratios in 100 pL of complete medium. Serum or medium blanks were then added in a volume of 50 pL and plates were centrifuged at 300 X g for 3 min before incubation. Control conditions included target cells alone (for spontaneous release), target cells and effector cells alone (for NKC), and target and effector cells plus HIV antibody or negative sera (for ADCC). Triplicate wells were used for each condition. After incubation (4 h for lymphocytes and PBMC and 18 h for monocytemacrophages unless otherwise specified), 100 pL of supernatant were harvested from each well (sample A), and the remaining 100 pL and cell pellet were separately collected after decontamination and solubilization with 50 gL of 50% sodium hypochlorite (sample B). Percent of radioactivity released was calculated as follows:
x 100 NKC and ADCC of the HXB targets were calculated as follows: Four h of incubation was found to be optimal for demonstration ofADCC and NKC by PBMC. In 4-h assays, spontaneous release by target cells averaged 7.5 % (SD 2.4%), and at 18 h, 32.6% (SD 5.3%). NKC and ADCC of HXB-infected cells were approximately log linear with respect to effector-to-target ratio when tested in the range of 25: 1 to 100: 1 (data not shown). A ratio of 50: 1 was used in further experiments examining PBMC subsets.
Statistical analysis. Significant ADCC was defined as lysis by effectors and positive sera that exceeded the mean + 2 SD of the lysis value by effectors and HIV-negative sera in triplicate wells for each experimental condition. This value corresponded to approximately 6% ADCC when 10 HIV-negative sera were assayed simultaneously with PBMC effector cells. Because cytotoxicity values for each group compared were not in every case normally distributed, the Wilcoxon signed rank test was used as a nonparametric test for the comparison of effector cell capacity of PBMC from adults and neonates. The t test was used to compare the relative percentage of ADCC values by neonatal and adult effectors.
RESULTS

Characterization of HZV-specific cytotoxicity assay. With
PBMC from normal adults, the HIV-seropositive reference pool mediated significant ADCC against HXB-infected cells at final dilution as high as 1: 10 000 (Fig. 1) . A prozone effect-diminished cytotoxicity with more concentrated sera-was observed in most experiments with dilution of the reference pool less than 1:100 (Fig. 1) . When the serum pool was tested with uninfected H9 cells, no enhancement of lysis was seen when compared with HIV-negative sera.
Characterization of HZV-speciJic ADCC by effector cell subsets. Because the cytotoxic activities of leukocyte subsets have been found to differ in other systems (9, 10, 22) , we characterized the cells responsible for HIV-specific ADCC. PMN from adults mediated only weak ADCC and NKC cytotoxicity of the HXB targets, with ADCC values consistently less than 10% even at effector-to-target ratios up to 100: 1 and with antiserum dilutions as low as 1:20 (Fig. 2) . PMN from neonates displayed similarly low capacity for ADCC of the HXB-2 cells (data not shown). Mononuclear cell fractions were therefore studied more intensively.
In the herpes simplex virus model, lymphocytes and monocytes differ in their kinetics and dependence on antiserum concentration for efficient ADCC (22) . A kinetic analysis of HIVspecific ADCC by adult lymphocytes and monocytes was performed by measuring ADCC after incubation periods of 3 to 18 h with optimal antibody concentrations for each cell type (l:20 dilution for adherent cells and 1: 100 for nonadherent cells, see below) (Fig. 3) . The lymphocytes obtained from healthy adults showed maximal ADCC after 6 h of incubation, with a plateau thereafter (Fig. 3A) . This time curve resembled that of ADCC by bulk PBMC (data not shown). In contrast, ADCC mediated by monocytes increased gradually through 18 h of incubation (Fig. 3B) . Longer 
The antibody dependence of lymphocytes for ADCC of HIVinfected cells was found to be similar to bulk PBMC: significant ADCC was seen at dilutions of the reference serum as high as 1: lo4, and a prozone effect was regularly seen with reference serum more concentrated than a 1:102 dilution (Fig. 4A) . In
Hours of incubation
Hours of incubation contrast, monocytes showed much less ADCC at high dilutions of serum but demonstrated increased ADCC in the most concentrated sera tested (Fig. 4B) .
Latex beads are reported to efficiently inhibit ADCC by monocyte-macrophages. When latex was added to effector cell subsets before incubation with targets, significant inhibition of ADCC was seen with purified monocyte-macrophages, whereas lymphocyte ADCC was little affected (Table 1) .
Defective HIV-specific ADCC by cord blood PBMC. Because developmental defects in antiviral cytotoxicity have been observed toward cells infected with viruses other than HIV (17, 23) , we compared the effector cell capacity of leukocytes from healthy infants and adults in the NKC and ADCC HIV assay. Umbilical cord blood samples collected at the same time as blood samples from healthy adult volunteers were tested in pairs in the cytotoxicity assay to minimize artifacts from interassay variability. Standard sera were diluted 1:200 for determination of ADCC because this dilution yielded the highest values for ADCC by PBMC from both adults and neonates. NKC of HIV-infected target cells by adult and cord blood PBMC was comparable at each effector-to-target ratio from 25: 1 to 100: 1 (Fig. 5A) . However, when ADCC of HIV-infected targets by PBMC from neonates and adults were compared, a significant deficit in the cytotoxic capacity of the neonatal effectors was seen ( p < 0.054
by Wilcoxon signed rank test) (Fig. 5B) . Despite a wide variability between individuals for ADCC activity, differences in percentage of ADCC by PBMC obtained from umbilical cord and adult blood were statistically significant at each of the effector-to-target ratios studied. When neonatal cytotoxic capacity was calculated as a percentage of the adult value and data from all effector-totarget ratios were pooled, neonates' NKC capacity was 101 % (+ 11 % SEM) of that of adults ( p = 0.932 by t test) and neonates' mean ADCC activity was 5 1 k 15% of that of adults ( p = 0.003 by t test).
To be certain that the intact NKC was not due to the effects of delivery and possible up-regulation on NKC, a small number of experiments were performed using PBMC obtained from healthy babies in the first days of life. There was no difference in neonates' NKC (mean & SEM in six or seven experiments at an effector-to-target cell ratio of 25: 1 and 50: 1, respectively = 15.0 In a limited number of studies, effector cells were tested against uninfected parent cells (H9) of the HXB-IIIB-infected cells. At an effector-to-target cell ratio of 25:1, higher NKC to H9 cells than to HXB-IIIB-infected cells was seen using both cord PBMC (55.8 + 6.9 versus 44.8 f 10.7, respectively) and adult cells (36.0 k 4.9 versus 18.9 & 6.1, respectively).
DISCUSSION
Using a well-characterized and reproducible assay, we have shown a marked defect in normal neonates' capacity for ADCC of HIV-infected cells. NKC of HIV-infected cells by PBMC from neonates, however, was comparable to that of cells from adults. This was surprising because several studies have documented deficiencies in neonatal NKC of tumor cell lines (1 6, 18, 19) or virus-infected cells (17) . Our findings may result from altered susceptibility to natural killer lysis of target cell lines after infection with HIV (24, 25). Alternatively, interferon-a production induced by HIV-infected targets (26) may enhance NKC selectively in the neonate (16) . Indeed, neonates' PBMC have been found to be as effective as adults' in NKC of human T-cell lymphotrophic virus-1-infected target cells (23) . However, the striking difference we observed between adults and neonates in ADCC capacity suggests that a developmental defect in this mode of antiviral activity may exist in the human neonate. Natural killer cells appear to be the chief effector cells for both NKC and ADCC of HIV-infected targets (5, 6) , and these two immune responses are initiated by the same cell receptor complex (27) . However, NKC and ADCC may use different cell signal transduction mechanisms (7) and different cytotoxic mechanisms (8, 28) . NKC and ADCC also may play different roles in the immune defense against, and pathogenesis of, HIV infection at different stages of illness or in different hosts. Leukocytes from HIV-infected adults have been reported to have defects in NKC against HIV-infected target cells, although ADCC capacity in these individuals was normal (29-3 1) . Our data suggest that a different defect in immune defense against HIV may exist in the normal newborn. Studies of HIV-infected children have emphasized cellular defects in ADCC lysis of HIV-infected cells (10, 32) . It has been hypothesized that HIV-specific ADCC may be deleterious to the adult host with established HIV infection by contributing to the destruction of infected CD4 lymphocytes (3 1). However, in an HIV-infected child, augmentation of anti-HIV ADCC through administration of HIV hyperimmune globulin has been observed to result in clinical improvement (33).
In the fetus and neonate at risk of vertical transmission of HIV, ADCC may play a protective role. In models of vertical transmission of murine leukemia virus and feline leukemia virus, providing antiserum to viral envelope glycoprotein to newborns protects against viremia and the development of leukemia (34, 35) . The single study to date of anti-HIV ADCC titers in newborns at risk of infection included only a few neonates but suggested a possible correlation between transplacental HIV ADCC titers at birth and protection from infection (36). If this correlation is proven, it would agree with the HSV mode1 (37) and other retroviral systems (34, 35) in which antiviral antibody in neonates protects against infection or severe disease.
For such immunotherapy to succeed, however, naive neonatal effector cells must be competent for lysis. The neonatal ADCC deficit we demonstrated against HIV-infected cells is also seen in the HSV system (17, 37) . Rational therapies to specifically augment this effector cell function must await the delineation of the specific defect, which may include effector-target binding, competence for lysis, or recycle steps (17, 38) .
The cell that predominantly directs anti-HIV ADCC in vivo is not yet identified. The antibody dependence, kinetics, and latexinhibition sensitivity of ADCC in the HIV system are notably similar to what has been reported for HSV (22) . Lymphocyte ADCC of HIV-infected cells was not inhibited by latex incubation, which ablated monocyte ADCC (Table 1) . Lymphocytes also mediated faster responses, and at lower antibody concentrations, than did monocytes (Figs. 3 and 4) . These data suggest that, under conditions that may be present in vivo, monocytes may be as competent as lymphocytes in anti-HIV ADCC. This finding is at variance with the report from another group that found that normal individuals' monocytes mediated only low levels of ADCC to HIV targets (9) . This discrepancy is likely due to methodologic differences, including the use of tumor necrosis factor-resistant target cells, labeling of cells with killed virus rather than active infection, and overnight incubation of effectors before use in cytotoxicity assay. The important differences in the conditions necessary for observation of optimal in vitro ADCC by each effector subset make direct comparison of the relative contribution of each impossible. Furthermore, the determination of each cell type's contribution to protective immune responses to HIV in vivo is even more speculative, owing to their different egress from the circulation into lymphoid tissue, reticuloendothelial cell organs, and the CNS, each of which may be a reservoir for HIV in infected children.
Our finding of a selective ADCC effector cell deficit in healthy neonates suggests that therapeutic approaches to enhance protective immune responses to HIV will have to be tailored to the host and to stage of disease. Augmenting cellular capacity for ADCC in the newborn at risk of HIV infection may be a viable strategy to intermpt vertical transmission.
